Levin, Papantonio, Thomas Mitchell, Rafferty & Proctor P.A.
Call Anytime 24 Hours - (888) 435-7001
OUR POLICIES - You Should Know:
- Our firm never releases any information given to us on these submission forms to any third party.
- This is considered a completely confidential and privileged communication.
- We do not store or release your email address to anyone. We do not engage in any kind of spamming activity.
- We will address immediately any concern you may have about how this communication is handled.
- We normally respond to email inquiries within 24 hours.
- $1 Billion Verdict in Go-Kart Burn Case
- $480 Million Verdict in Defective Single-Engine Aircraft
- $380 Million Verdict in Environmental Case
- $42 Million Verdict in Rezulin Case
- $42 Million Verdict in Fraud/RICO Case
- $31 Million Verdict in Medical Malpractice Case
- $30 Million Verdict in Tobacco Case
- $25 Million Verdict in Brain Injury Case
- $21 Million Verdict in Discrimination Case
- $18 Million Verdict in Train Derailment
- $13 Million Verdict in Automobile Accident
- $11 Million Verdict in Dental Malpractice
- $10 Million Verdict in Accutane Case
- $10 Million Verdict in Asbestos Case
- $10 Million Verdict in Breach of Contract Case
- $9 Million Verdict in Tobacco Case
- $9 Million Verdict in Brain Injury Case
- $8 Million Verdict in Fosamax Case
- $8 Million Verdict in DRAM Shop Case
- $7 Million Verdict Against Hartford Ins. Co.
- $5 Million Verdict in Airplane Crash
- $4.8 Million Verdict in Trucking Accident
- $4.3 Million Verdict in Electrocution Case
- $3.8 Million Verdict in Railroad Crossing Collision
- $3.6 Million Verdict in Negligent Publication of Toll Free Number
U.S. Department of Justice Launches Another Criminal Investigation of Merck
The Wall Street Journal reports that Merck & Co. has been issued a criminal investigation subpoena by the U.S. Department of Justice regarding how Merck marketed its brain tumor medication, Temodar; its hepatitis C drug, PegIntron; and its cancer treatment, Intron A. In an August 2011 filing with the Securities and Exchange Commission, Merck disclosed the subpoena as part of a “federal health-care investigation under criminal statutes”.
According to the August 9, 2011, Wall Street Journal article, Merck has been the subject of prior federal criminal probes concerning a range of healthcare fraud allegations, including Merck’s promotion of some drugs for nonapproved uses. One of these investigations concerns Merck’s albatross, Vioxx, for which Merck has reserved approximately $950 million for an emerging settlement in a federal investigation of how Merck researched, marketed, and sold Vioxx.
Learn more about Fosamax
Facebook
Twitter
Youtube
Our News